KUALA LUMPUR, OCT. 12 – Glycoprox Biosciences Corporation (GPX) from San Francisco of the United States of America has today inked an agreement with TPM Biotech Sdn Bhd (TPMB) to set up its base in Malaysia at Technology Park Malaysia, Bukit Jalil, Kuala Lumpur.

GPX combines next generation glycomics, robust and reproducible instrumentation (LC/MS) and deep machine learning to augment cancer diagnosis, biomarker and target discovery for the development of more efficacious therapeutics.

The collaboration agreement was signed between GPX’s Chief Executive Officer Mr. Aldo Carrascoso and President/Chief Executive Officer of Technology Park Malaysia YBhg Dato’ Ir. Mohd Azman Haji Shahidin, witnessed by YB Datuk Seri Panglima Wilfred Madius Tangau, Minister of Science, Technology and Innovation, at the National Innovation and Creativity Economy 2017 (NICE 2017) exhibition.

Also present at the document exchange ceremony were Technology Park Malaysia Corporation Sdn Bhd (TPM) Chairman, YB Dato’ Ahmad Fauzi Zahari and its TPM Biotech Head, Puan Ema Ukhtiah Zakaria, as well as key officials from Malaysian Bioeconomy Corporation Sdn Bhd and captains of biotechnology industry.

YBhg Dato’ Ir. Mohd Azman said the setting up of GPX’s base at TPMB’s molecular science laboratory is testimony of the former’s confidence in the state-of-the-art facilities and services available for the furtherance of their research and development programmes in Malaysia and South East Asia.

We are indeed delighted to have a renowned company such as GPX to choose their operation base in Technology Park Malaysia and to collaborate with TPM Biotech, Azman added.

Meanwhile, Mr. Aldo Carrascoso said the current cancer drug development industry is very limited in approach as it mostly focuses on using DNA-, RNA- based systems and methodologies.

“There are almost no glycoproteomics projects that are funded even though target discovery and validation is hit-miss with traditional methods, hence making the de facto treatment radiation, surgical or chemotherapy based. Recent ground-breaking peer-reviewed research in Glycomics had proven that glycosylation patterns are viable biomarkers for cancer.

“GPX will be the first to commercialize this groundbreaking research on Glycomics for target discovery and validation, the first to utilize advanced instrumentation at its core and the first to use next generation artificial intelligence to process data to identify undiscovered signals and markers. This approach will drastically reduce the time to identify and validate new glycan-based cancer targets.

“Our US Scientists and Computational Engineers are excited to explore the opportunities provided by Malaysia in biotechnology and life sciences. We chose Malaysia as our first site for the global studies due to its impressive ecosystem, knowledgeable local talents and the strong support from the government and the industry” he said.

GPX was founded by a South San Francisco-based team of serial entrepreneurs with repeated and proven track record of success, value creation and execution in the fields of Machine Learning, Analytical Chemistry through Liquid Chromatography/Mass Spectrometry and in Oncological Glycoproteomics.

TPM Biotech, a subsidiary of Technology Park Malaysia Corporation Sdn Bhd, has earned internationally recognized accreditations with ISO9001:2008 and IEC 17025 certifications. In addition, its functional food processing area is a HACCP accredited facility. All these accreditations, certifications and large commercial production capacity make TPM Biotech the preferred choice for grassroots entrepreneur products and services.

 — Ends —